Most Popular
-
1
N. Korea decides to expel US soldier Travis King
-
2
Lee Jae-myung's arrest reprieve emboldens opposition fightback
-
3
New teachers’ manual bans recording devices in classrooms
-
4
At 93 and on quest to become Korea's oldest Ph.D. grad
-
5
‘Do you know Dr. Hong?’ Moms say they wish they didn’t
-
6
BTS agency likely to face tougher disclosure rules
-
7
Traffic jammed on highways ahead of extended Chuseok holiday
-
8
[Herald Interview] 'UN peacekeeping forces need better gender equity'
![[Herald Interview] 'UN peacekeeping forces need better gender equity'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/26/20230926000473_0.jpg&u=20230927094737)
-
9
Walking can help ease depression, suicidal impulse: study
-
10
Hospital visits during Chuseok cost up to 50% more
![[Herald Interview] 'UN peacekeeping forces need better gender equity'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2023/09/26/20230926000473_0.jpg&u=20230927094737)
Celltrion’s COVID-19 treatment gets safety nod in Australia
By Kan Hyeong-wooPublished : Feb. 7, 2022 - 13:53
Celltrion has confirmed the safety of its inhalable antibody treatment for COVID-19 in a phase one clinical trial in Australia, the pharmaceutical company said Monday.
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
Celltrion’s US partner Inhalon Biopharma completed the planned administering of the drugs for 24 volunteers after it acquired testing approval from the Australian Therapeutic Goods Administration in August.
The results of the clinical trial proved the drug’s safety, as there were no serious adverse events from inhaling the drug or no stoppages in administering the drug due to adverse events, the company said.
On top of the latest safety check, Celltrion also submitted an application to conduct a global phase three clinical trial of its COVID-19 antibody cocktail therapy -- a combination of monoclonal antibodies -- in Bosnia, North Macedonia and Serbia. The company plans to test the cocktail treatment on 2,200 coronavirus patients to show the efficacy and safety of the drug.
More from Headlines
![[Today’s K-pop] Blackpink tops 1.5b views with ‘How You Like That’ dance video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2023/09/27/20230927000614_0.jpg&u=20230927184705)
